The J-Plasma handpiece will be powered by Bovie’s GS electrosurgical generator, which has also previously obtained 510k market clearance.
“This is a significant development toward Bovie becoming a leader in plasma surgery and achieving increased prominence in the electrosurgery marketplace,” Bovie CEO Andrew Makrides stated in the press release.
Bovie recently received a United States patent for a “Method to generate a plasma stream for performing electrosurgery,” adding to the company’s J-Plasma™ patent portfolio of four patents and three additional patent applications pending.
Bovie said it will continue to explore and review added applications for J-Plasma, which include gynecology, dermatology, plastic surgery, infection control, use in robotics, and other surgical techniques. In addition, it plans to introduce J-Plasma at selected hospital beta sites and several university teaching facilities to prepare for market launch later this year.
The J-Plasma device passes an inert gas such as helium over a sharp conductive point that produces a luminous discharge beam. This sharp conductive point can also be in the form of a retractable surgical blade, which can be used for incisions and other cutting procedures; when retracted, the blade is used to form the J-Plasma beam for coagulation.
For more information visit www.boviemed.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
